Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jan 2, 2021
Date Accepted: Nov 27, 2021

The final, peer-reviewed published version of this preprint can be found here:

An Android-Based Mobile App (ARVPredictor) for the Detection of HIV Drug-Resistance Mutations and Treatment at the Point of Care: Development Study

Ongadi BA, Lihana RW, Kiiru JN, Ngayo MO, Obiero G

An Android-Based Mobile App (ARVPredictor) for the Detection of HIV Drug-Resistance Mutations and Treatment at the Point of Care: Development Study

JMIR Form Res 2022;6(2):e26891

DOI: 10.2196/26891

PMID: 35107425

PMCID: 8851341

©ARVPredictor: Android-based mobile application for the detection of HIV drug resistance mutations and treatment at the point of care.

  • Beatrice A. Ongadi; 
  • Raphael W. Lihana; 
  • John N. Kiiru; 
  • Musa O. Ngayo; 
  • George Obiero

ABSTRACT

Background:

HIV/AIDS is still one of the major global human health challenges especially in resource limited environments. By 2017, over 77.3 million people were infected with the disease and about 35.4 million individuals already died from AIDS-related illnesses. Around the same time over 21.7 million people were accessing ART with significant clinical outcomes. However, numerous challenges are experienced in delivery and accurate interpretation of HIV patients’ data by various care givers at different care levels. Mobile health technology is progressively making inroads into the health sector as well as medical research. Different mobile devices have become common in health care settings leading to rapid growth in the development of downloadable softwares specifically designed to fulfill particular health related purposes.

Objective:

We developed a mobile based application called ©ARVPredictor and showed that it can accurately define HIV-1 drug resistance mutations targeting the HIV pol gene for use at the point of care

Methods:

©ARVPredictor was designed using Android Studio with Java as the programming language and set for both Android and iOS. The application system is hosted on Nginx Server and network calls built on PHP’s Lavarel framework handled by Retrofit Library. Digital Ocean offers high performance and stable cloud computing platform for ©ARVPredictor. This mobile application is enlisted in the play store (https://play.google.com/store/apps/details?id=co.ke.ikocare) as “ARV Predictor” and Source code available under MIT permissive License at the following GitHub repository https://github.com/bongadi/ARV_Predictor_App_OngadiBA

Results:

The mobile based application (©ARVPredictor) takes in a set of sequences or known mutations (protease, reverse transcriptase and integrase). It then returns inferred levels of resistance to selected nucleoside, non-nucleoside protease and integrase inhibitors for accurate HIV/AIDS management at the point of care.

Conclusions:

The application achieves the overall aim of providing a solution to HIV/AIDS care givers at the point of care. Within a record turnaround time the caregiver is capable of determining the HIV drug resistance mutation and identify the patients’ appropriate line of management.


 Citation

Please cite as:

Ongadi BA, Lihana RW, Kiiru JN, Ngayo MO, Obiero G

An Android-Based Mobile App (ARVPredictor) for the Detection of HIV Drug-Resistance Mutations and Treatment at the Point of Care: Development Study

JMIR Form Res 2022;6(2):e26891

DOI: 10.2196/26891

PMID: 35107425

PMCID: 8851341

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.